US Bancorp
AVLN icon

US Bancorp’s Avalyn Pharma AVLN Stock Holding History

US Bancorp’s Portfolio AVLN Stock Details AVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$285 Buy
+10
New +$323 ﹤0.01% 4166

Other funds holding AVLN

Andera Partners
Andera Partners Paris $176M AUM 1.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Lewis Asset Management
Lewis Asset Management Lafayette, California $294M AUM 25.62% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

US Bancorp's AVLN Position: Q3 2026 in Review

US Bancorp opened a new position in Avalyn Pharma (AVLN) in Q3 2026: 10 shares worth $285. The stake represents ﹤0.01% of the portfolio and ranks #4166 among its holdings.

23 funds tracked by Wall St. Rank hold AVLN as of Q3 2026.

  • US Bancorp held 10 shares of Avalyn Pharma worth $285 as of Q3 2026.
  • Avalyn Pharma was a new US Bancorp position in Q3 2026.
  • Avalyn Pharma made up ﹤0.01% of US Bancorp's portfolio in Q3 2026, its #4166 holding.
  • 23 funds tracked by Wall St. Rank held Avalyn Pharma as of Q3 2026.

Based on US Bancorp's 13F filing for Q3 2026, filed 5 Nov 2026.